This is the first oral antiviral to get through the regulatory process and is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

FMT is a promising intervention for immunocompetent patients with recurrent C difficile infection. However, the safety of FMT remains inconclusive due to limited data on serious adverse events and mortality.

Sulbactam-durlobactam (Xacduro) was developed to treat the troublesome Acinetobacter baumannii pathogen that can be associated with bacterial pneumonia.

Screening and treating immigrants for hepatitis C virus infection may be instrumental to eliminating the disease in Canada.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

Five-year cumulative data from 2 phase 3 studies looked at 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy).

Accelerating bivalent booster vaccine campaigns for children could reduce pediatric hospitalizations and school absenteeism.

Anticoagulant treatment for 3 to 6 months was sufficient for the majority of COVID-19 patients with venous thromboembolism, the study authors found.

Education is vital to this group and can help in working towards reducing viral hepatitis.

Today, we celebrate the crucial role of infectious disease pharmacists in combating infectious diseases and promoting patient safety.

Pfizer's RSVpreF vaccine candidate has shown promising efficacy in preventing severe lower respiratory illness caused by RSV in infants. With the potential approval of RSVpreF, pediatric care could undergo a significant positive change.

The National Institute for Health and Care Excellence (NICE) believes National Health Service (NHS) can use bulevirtide as a treatment option.

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

By implementing rapid point-of-care HCV RNA testing in supervised consumption services, a study achieved high testing acceptance and successful engagement with HCV care among individuals who inject drugs.

Stay informed with this concise summary of the week's most significant stories.

A vaccine developer discusses the benefits of this approach and the development behind them.

RSVpreF receives strong support from the FDA's VRBPAC, with positive votes for efficacy and safety. The vaccine shows promise in preventing severe respiratory illness in infants, and an FDA authorization decision is expected in August 2023.

Expanding peripartum prophylaxis could be more cost-effective, but would likely lead to significant over-treatment.

These new tests, conducted in a single tube within minutes, could enable at-home testing for various diseases. By incorporating CRISPR technology, the test achieves high reliability by distinguishing between false and true positives.

Aerobic activity and muscle strengthening exercises reduced the risk of pneumonia or influenza mortality, even when the exercises were completed less frequently than recommended.

Under its final guidance, all prospective blood donors will answer a series of individual, risk-based questions to determine eligibility.

LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.

AI tools have taken front and center stage in 2023. One area of interest is how the new technology can be applied in infectious disease surveillance. A new article in the New England Journal of Medicine explores this concept.

While African American/Black participants were less likely to meet treatment criteria, treatment receipt did not significantly differ by race, indicating equitable access to treatment.

The recommendations look to increase usage of the antiviral and decrease the routine use of the recombinant IL-1 inhibitor for COVID-19 treatment.